Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers

Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers

Collection:
Health Policy and Services Research
Series Title(s):
Research brief (Leonard Davis Institute of Health Economics)
Author(s):
Doshi, Jalpa A., author
Puckett, Justin T., author
Parmacek, Michael S., author
Rader, Daniel J., author
Contributor(s):
Leonard Davis Institute of Health Economics, issuing body.
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Language(s):
English
Format:
Text
Subject(s):
Eligibility Determination
Insurance Coverage
Insurance, Health
PCSK9 Inhibitors
Serine Proteinase Inhibitors -- economics
Serine Proteinase Inhibitors -- therapeutic use
Pennsylvania
United States
Genre(s):
Technical Report
Abstract:
Key Findings. A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found unusually complex and burdensome demands across public and private insurance plans in the United States. These findings raise concerns that current policies may create undue barriers to care even in medically appropriate patients, particularly since requirements were just as stringent for patients with a genetic condition that creates more clear-cut eligibility for PCSK9 inhibitor treatment.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (2 unnumbered pages))
Illustrations:
Illustrations and Portraits
NLM Unique ID:
101731578 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101731578